Degussa (Germany) dental performing well:
This article was originally published in Clinica
Results at Degussa's (Germany) dental division improved during the first six months of fiscal 1995 (ended March 31st), according to the company. The group as a whole saw sales rise 9% to DM 7,300 million ($5,034 million) with pre-tax income up 51% at DM 183 million. The group expects earnings growth to continue during the year, although high payroll costs and the strong German mark will depress results.
You may also be interested in...
The Swiss giant is hoping to get seven more approvals for its blockbuster immunology drug over the next 10 years.
Cadila has filed for approval of saroglitazar for NASH in India. The drug, which could emerge as the first medicine for the indication if approved, is already being used by a million Indian patients for diabetic dyslipidemia and hypertriglyceridemia.
It has been a long and sometimes tortuous development path for Lupuzor but ImmuPharma's chief executive tells Scrip the company's faith in the lupus drug is bearing fruit.